Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

Blood (2022) 140 (Supplement 1): 6592–6593.

https://doi.org/10.1182/blood-2022-171149

Published: 2022

Journal Articles

Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease

Dong Won Baek, Sr., Joon Ho Moon, Jae-Sook Ahn, Seong Kyu Park, Ik Chan Song, Ho-Sup Lee, Won Sik Lee, Jong Ho Won, Hong Ghi Lee, June-Won Cheong, Yeung-Chul Mun, Chul W. Jung, Je-Hwan Lee, Hyeoung-Joon Kim, Sang Kyun Sohn

Blood (2021) 138 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2021-154470

Published: 2021

Journal Articles

Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT

Blood (2021) 138 (Supplement 1): 3757.

https://doi.org/10.1182/blood-2021-152008

Published: 2021

Journal Articles

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Sung-Eun Lee, MD PhD, Joon Seong Park, MD, Young Rok Do, PhDMD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Jae-Yong Kwak, Jeong-A Kim, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Dong-Wook Kim, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139253

Published: 2020

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Ho Sup Lee, MD PhD, Chang-Ki Min, MD PhD, Kihyun Kim, MD, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, MD PhD, Dok Hyun Yoon, MD PhD, Cheolwon Suh, Ho-Jin Shin, MD PhD, Yeung-Chul Mun, MD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, Hye Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3114.

https://doi.org/10.1182/blood-2019-122404

Published: 2019

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y

Hawk Kim, MD PhD, Yunsuk Choi, MD, Sung-Soo Yoon, MD PhD, Soo-Mee Bang, MD PhD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Yeung-Chul Mun, Young Rok Do, PhD MD, Yong Park, MD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Ho Sup Lee, MD, Min Kyoung Kim, MD PhD, Won-Sik Lee, Jeong-Yeal Ahn, MD, Kyoo-Hyung Lee, MD PhD

Blood (2018) 132 (Supplement 1): 3876.

https://doi.org/10.1182/blood-2018-99-116190

Published: 2018

Journal Articles

Inhibition of Autophagy with 3-Methyladenine Potentiates Bortezomib-Induced Apoptosis of Myeloma Cell Via up Regulation of Mitochondrial Reactive Oxygen Species

Yeung-Chul Mun, Jee Young Ahn, Eun Sun Yoo, Kyoung Eun Lee, Eunmi Nam, Soon Nam Lee, Hyun Ae Woo, Sue Goo Rhee, Chu Myong Seong

Blood (2018) 132 (Supplement 1): 4472.

https://doi.org/10.1182/blood-2018-99-117727

Published: 2018

Journal Articles

Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study

Dae Young Zang, MD PhD, Won Sik Lee, MD PhD, Yeung-Chul Mun, Young Rok Do, PhD MD, Sukjoong Oh, MD PhD, Sung-Eun Lee, MD PhD, Soo Young Choi, Dong-Wook Kim, MD PhD

Blood (2018) 132 (Supplement 1): 4252.

https://doi.org/10.1182/blood-2018-99-118026

Published: 2018

Journal Articles

The Assessment of Health-Related Quality of Life in Relapsed or Refractory Myeloma Patients Receiving Lenalidomide and Low Dose Dexamethasone: A Result of Hola Study

Seok Jin Kim, MD PhD, Yong Park, MD, Yeung-Chul Mun, Jin Seok Kim, MD PhD, Kihyun Kim, MD PhD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 4853.

https://doi.org/10.1182/blood-2018-99-115447

Published: 2018

Journal Articles

Prognostic Implication of Early Molecular Response at 3 Months in Chronic Myeloid Leukemia Patients: A Comparison of Imatinib and Second Generation Tyrosine Kinase Inhibitors

Dong-Wook Kim, MD PhD, Sung-Eun Lee, MD PhD, Soo Young Choi, Dae Young Zang, MD PhD, Won-Sik Lee, Yeung-Chul Mun, Young Rok Do, PhD MD, Sukjoong Oh, MD PhD

Blood (2018) 132 (Supplement 1): 3017.

https://doi.org/10.1182/blood-2018-99-117631

Published: 2018

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Blood (2017) 130 (Supplement 1): 317.

https://doi.org/10.1182/blood.V130.Suppl_1.317.317

Published: 2017

Journal Articles

Long-Term Rivaroxaban for the Treatment of Acute Venous Thromboembolism in Patients with Active Cancer in a Prospective Multicenter Trial: KVTE13-01

Ho-Young Yhim, MD, Won-Il Choi, MD, Sung-Hyun Kim, MD PhD, Seung-Hyun Nam, MD, Kyoung Ha Kim, Yeung-Chul Mun, MD PhD, Hun-Gyu Hwang, MD, Doyeun Oh, MD, Keun-Wook Lee, MD, Eun-Kee Song, MD, Yong Shik Kwon, MD, Soo-Mee Bang, MD PhD

Blood (2017) 130 (Supplement 1): 3711.

https://doi.org/10.1182/blood.V130.Suppl_1.3711.3711

Published: 2017

Journal Articles

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

Sukjoong Oh, Ki Hoon Kang, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 2864.

https://doi.org/10.1182/blood.V130.Suppl_1.2864.2864

Published: 2017

Journal Articles

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

Sung-Eun Lee, MD, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, Yeung-Chul Mun, MD PhD, Young-Woong Won, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 2873.

https://doi.org/10.1182/blood.V130.Suppl_1.2873.2873

Published: 2017

Journal Articles

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

Blood (2017) 130 (Supplement 1): 3130.

https://doi.org/10.1182/blood.V130.Suppl_1.3130.3130

Published: 2017

Journal Articles

Bleeding Complications in CAT Patients Treated with LMWH or DOACs

Kyoung Ha Kim, Ho-Young Yhim, MD, Won-Il Choi, Sung-Hyun Kim, MD PhD, Yeung-Chul Mun, MD PhD, Soo-Mee Bang, MD PhD, Doyeun Oh, MD, Ji Hyun Lee, MD PhD, Ji Yun Lee, MD

Blood (2017) 130 (Supplement 1): 4914.

https://doi.org/10.1182/blood.V130.Suppl_1.4914.4914

Published: 2017

Journal Articles

the Safety and Efficacy of Pomalidomide in Combination with Cyclophosphamide and Dexamethasone (PCD) in the Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-Labeled, Multicenter Phase II Study

Ho Sup Lee, MD, Chang-Ki Min, MD PhD, Kihyun Kim, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, Dok Hyun Yoon, MD PhD, Cheolwon Suh, MD PhD, Ho-Jin Shin, MD, Yeung-Chul Mun, MD PhD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, MD PhD, Hye Jin Kang, MD PhD, Sung-Soo Yoon, MD PhD

Blood (2017) 130 (Supplement 1): 1834.

https://doi.org/10.1182/blood.V130.Suppl_1.1834.1834

Published: 2017

NARROW

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease

Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y

Inhibition of Autophagy with 3-Methyladenine Potentiates Bortezomib-Induced Apoptosis of Myeloma Cell Via up Regulation of Mitochondrial Reactive Oxygen Species

Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study

The Assessment of Health-Related Quality of Life in Relapsed or Refractory Myeloma Patients Receiving Lenalidomide and Low Dose Dexamethasone: A Result of Hola Study

Prognostic Implication of Early Molecular Response at 3 Months in Chronic Myeloid Leukemia Patients: A Comparison of Imatinib and Second Generation Tyrosine Kinase Inhibitors

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Long-Term Rivaroxaban for the Treatment of Acute Venous Thromboembolism in Patients with Active Cancer in a Prospective Multicenter Trial: KVTE13-01

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

Bleeding Complications in CAT Patients Treated with LMWH or DOACs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only